Last 48 quarters of trend data · Healthcare · Drug Manufacturers - Specialty & Generic
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q4 '26 | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 28.66 | 14.81 | 23.44 | 13.94 | 15.56 | 15.20 | 10.47 | 65.63 | 33.12 | 225.40 | 15.39 | 96.50 | — | 12.23 | 15.32 | 18.63 | 33.22 | 26.57 | 11.34 | 11.87 | 33.66 |
| — | -2.6% | +123.8% | -78.8% | -53.0% | -93.3% | -32.0% | -32.0% | — | +1742.7% | +0.5% | +418.1% | — | -54.0% | +35.2% | +56.9% | -1.3% | +54.6% | -44.3% | -21.7% | +132.1% | |
| P/S Ratio | 1.07 | 0.81 | 1.48 | 1.02 | 1.14 | 0.69 | 0.62 | 0.69 | 0.88 | 0.62 | 0.50 | 0.47 | 0.56 | 0.54 | 0.63 | 0.56 | 0.58 | 0.76 | 0.84 | 0.89 | 1.02 |
| — | +18.2% | +136.7% | +48.0% | +29.5% | +10.3% | +25.6% | +47.3% | +57.0% | +14.3% | -21.2% | -15.5% | -3.4% | -28.3% | -25.1% | -37.5% | -43.0% | -42.8% | -27.8% | -6.9% | +12.6% | |
| P/B Ratio | 4.86 | 3.34 | 6.27 | 4.60 | 5.31 | 3.64 | 3.27 | 3.46 | 3.54 | 2.65 | 1.94 | 1.73 | 1.89 | 1.96 | 2.28 | 2.02 | 2.05 | 2.95 | 3.03 | 3.46 | 3.74 |
| — | -8.2% | +91.9% | +32.9% | +50.1% | +37.4% | +68.5% | +100.0% | +86.6% | +34.8% | -14.9% | -14.4% | -7.6% | -33.5% | -24.7% | -41.4% | -45.2% | -39.8% | -33.9% | -6.3% | +2.1% | |
| P/FCF | 33.05 | 61.60 | 637.57 | 46.34 | — | 31.96 | 6.14 | — | 75.18 | 11.06 | 78.10 | 5.69 | 14.82 | 14.84 | — | — | — | — | — | 16.63 | — |
| — | +92.7% | +10284.8% | — | — | +188.9% | -92.1% | — | +407.2% | -25.5% | — | — | — | — | — | — | — | — | — | +65.7% | — | |
| EV / EBITDA | 13.30 | 8.19 | 12.42 | 8.35 | 9.74 | 9.39 | 8.56 | 10.63 | 12.86 | 10.27 | 8.56 | 9.64 | 30.46 | 7.91 | 10.18 | 10.13 | 10.90 | 9.36 | 10.79 | 9.89 | 14.14 |
| — | -12.8% | +45.1% | -21.4% | -24.3% | -8.5% | +0.0% | +10.2% | -57.8% | +29.8% | -15.9% | -4.8% | +179.4% | -15.4% | -5.7% | +2.5% | -22.9% | -34.6% | -10.5% | -4.9% | +22.5% | |
| EV / EBIT | 18.79 | 11.84 | 17.38 | 11.36 | 11.89 | 13.41 | 10.18 | 28.16 | 19.31 | 23.35 | 13.61 | 26.44 | — | 9.59 | 13.89 | 14.90 | 26.92 | 18.73 | 10.01 | 11.31 | 25.38 |
| — | -11.7% | +70.6% | -59.7% | -38.4% | -42.6% | -25.2% | +6.5% | — | +143.4% | -2.0% | +77.4% | — | -48.8% | +38.7% | +31.7% | +6.1% | -7.2% | -38.9% | -24.9% | +79.8% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q4 '26 | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 30.9% | 33.9% | 32.6% | 35.5% | 32.9% | 29.0% | 30.1% | 32.9% | 32.1% | 31.9% | 30.2% | 31.5% | 29.3% | 30.1% | 30.7% | 31.6% | 29.5% | 30.7% | 29.9% | 30.4% | 30.1% |
| — | +16.6% | +8.3% | +7.7% | +2.7% | -8.9% | -0.6% | +4.7% | +9.5% | +6.1% | -1.7% | -0.6% | -0.8% | -2.2% | +2.9% | +4.2% | -2.0% | -3.1% | -8.5% | -8.3% | -8.3% | |
| Operating Margin | 8.5% | 12.1% | 12.5% | 14.6% | 13.2% | 8.9% | 9.6% | 8.3% | 6.8% | 6.7% | 7.6% | 6.3% | -0.3% | 9.3% | 7.6% | 6.5% | 5.9% | 9.0% | 8.0% | 9.6% | 6.8% |
| — | +36.3% | +29.8% | +76.3% | +93.7% | +32.1% | +27.3% | +31.4% | +2265.7% | -27.7% | +0.2% | -3.0% | -105.3% | +3.9% | -5.7% | -32.4% | -13.5% | +3.1% | -15.8% | -0.7% | -15.3% | |
| Net Margin | 3.7% | 5.5% | 6.3% | 7.3% | 7.3% | 4.5% | 6.0% | 1.0% | 2.7% | 0.3% | 3.2% | 0.5% | -3.5% | 4.5% | 4.1% | 2.9% | 1.7% | 2.9% | 7.4% | 7.5% | 3.0% |
| — | +20.3% | +4.3% | +613.0% | +172.2% | +1552.1% | +88.0% | +102.1% | +177.3% | -93.9% | -21.9% | -82.7% | -308.9% | +53.7% | -44.6% | -60.7% | -45.5% | -62.3% | +28.5% | +20.9% | -51.7% |
| Metric | TTM | Q4 '26 | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 17.8% | 5.8% | 6.9% | 8.5% | 8.9% | 6.2% | 8.1% | 1.3% | 2.7% | 0.3% | 3.1% | 0.5% | -2.9% | 4.1% | 3.7% | 2.7% | 1.5% | 2.8% | 7.0% | 7.4% | 2.8% |
| — | -7.0% | -15.0% | +576.4% | +228.0% | +2087.1% | +162.0% | +169.1% | +193.9% | -93.1% | -16.3% | -82.7% | -296.5% | +46.5% | -46.8% | -63.3% | -47.0% | -62.5% | +23.3% | +17.1% | -57.2% | |
| ROA | 4.1% | 1.5% | 1.7% | 2.0% | 1.9% | 1.3% | 1.6% | 0.3% | 0.7% | 0.1% | 0.9% | 0.1% | -0.8% | 1.2% | 1.0% | 0.8% | 0.4% | 0.8% | 2.0% | 2.1% | 0.8% |
| — | +14.6% | +5.1% | +595.5% | +169.8% | +1577.1% | +86.3% | +115.1% | +186.5% | -93.5% | -17.3% | -82.6% | -301.9% | +46.5% | -48.0% | -63.6% | -47.3% | -61.0% | +32.6% | +29.0% | -50.2% | |
| ROIC | 9.8% | 3.3% | 3.4% | 3.9% | 3.6% | 2.6% | 2.6% | 2.3% | 1.9% | 1.9% | 2.0% | 1.6% | -0.1% | 2.4% | 1.9% | 1.7% | 1.5% | 2.6% | 2.3% | 2.7% | 1.8% |
| — | +26.5% | +29.8% | +73.4% | +93.2% | +36.2% | +29.2% | +44.4% | +2657.2% | -19.9% | +5.3% | -7.4% | -104.8% | -9.5% | -16.7% | -37.0% | -13.5% | +9.0% | -11.6% | +5.8% | -14.4% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q4 '26 | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 2.67 | 2.05 | 2.18 | 2.33 | 2.52 | 2.67 | 2.89 | 3.20 | 1.98 | 2.05 | 1.94 | 1.89 | 1.90 | 1.81 | 1.90 | 1.91 | 1.91 | 1.79 | 1.71 | 1.82 | 1.88 |
| — | -23.2% | -24.8% | -27.3% | +27.2% | +30.2% | +49.5% | +68.8% | +4.3% | +13.4% | +1.9% | -0.6% | -0.9% | +0.7% | +11.4% | +5.0% | +1.8% | +0.2% | -10.9% | -5.7% | -14.1% | |
| Debt / EBITDA | 4.88 | 12.83 | 13.03 | 11.49 | 12.93 | 16.51 | 16.69 | 21.28 | 19.17 | 19.03 | 17.96 | 20.85 | 63.64 | 15.77 | 19.14 | 21.02 | 22.73 | 15.04 | 16.49 | 14.35 | 19.54 |
| — | -22.3% | -21.9% | -46.0% | -32.6% | -13.2% | -7.1% | +2.0% | -69.9% | +20.7% | -6.2% | -0.8% | +180.0% | +4.9% | +16.1% | +46.5% | +16.3% | -4.9% | +11.8% | -2.3% | +10.0% | |
| Current Ratio | 2.76 | 2.96 | 3.17 | 3.05 | 3.09 | 2.76 | 2.91 | 3.20 | 3.23 | 2.94 | 3.16 | 3.12 | 3.39 | 3.33 | 3.54 | 3.47 | 3.30 | 2.97 | 2.92 | 3.05 | 3.27 |
| — | +7.0% | +8.9% | -4.6% | -4.1% | -6.2% | -7.8% | +2.4% | -4.8% | -11.5% | -10.8% | -10.0% | +2.6% | +12.2% | +21.3% | +13.7% | +1.1% | -2.4% | +4.6% | +6.8% | +13.3% | |
| Quick Ratio | 1.25 | 1.27 | 1.26 | 1.22 | 1.35 | 1.25 | 1.23 | 1.37 | 1.69 | 1.64 | 1.67 | 1.60 | 1.77 | 1.75 | 1.77 | 1.75 | 1.68 | 1.61 | 1.59 | 1.67 | 1.82 |
| — | +1.5% | +2.3% | -10.7% | -20.1% | -24.0% | -26.2% | -14.4% | -4.8% | -6.3% | -5.9% | -8.5% | +5.6% | +8.8% | +11.7% | +4.8% | -7.7% | -6.6% | +0.8% | +5.5% | +13.2% | |
| Interest Coverage | 3.04 | 4.18 | 3.97 | 3.79 | 3.69 | 3.82 | 2.96 | 1.53 | 2.18 | 2.12 | 1.97 | 0.96 | -0.72 | 3.03 | 2.51 | 2.39 | 1.83 | 5.10 | 12.97 | 6.66 | 3.18 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying PAHC stock.
Phibro Animal Health Corporation's current P/E is 28.7x. The average P/E over the last 4 quarters is 16.9x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Phibro Animal Health Corporation's current operating margin is 8.5%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Phibro Animal Health Corporation's business trajectory between earnings reports.